RxDoctor Payments Data

Svetlana Khandros

Family Medicine · Brooklyn, NYNPI 1871578872

Payments from drug & device makers

$750in general payments, 2019–2025

Across 24 payments — averaging $31.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$284
  • AbbVie$149
  • AstraZeneca$124
  • Sanofi-aventis U.S. LLC$43
  • Boehringer Ingelheim$40
  • Amarin Pharma, Inc.$39
  • plus $72 from 3 others

What the payments were for

  • Food & beverage$750100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$750 in reported general payments places this provider in the 60th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$208,580
Medicare patients
150
Services billed
3,364

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate102$73,429
BiktarvyBictegrav/Emtricit/Tenofov Ala11$39,334
OzempicSemaglutide31$32,029
JardianceEmpagliflozin47$31,594
DescovyEmtricitabine/Tenofov Alafenam15$31,080
ZenpepLipase/Protease/Amylase17$24,454
VascepaIcosapent Ethyl114$22,405
TrulicityDulaglutide15$21,588
CreonLipase/Protease/Amylase23$14,083
EliquisApixaban14$11,195
JanumetSitagliptin Phos/Metformin Hcl13$8,543
KerendiaFinerenone13$8,018
SymbicortBudesonide/Formoterol Fumarate29$7,975
TradjentaLinagliptin16$7,851
Synjardy XrEmpagliflozin/Metformin Hcl12$7,648

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr$40$47,09375 claims
AbbVieCreon, Linzess$149$21,45237 claims
AstraZenecaSymbicort, Breztri Aerosphere$124$15,22041 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,321 family medicine providers in New York.

Other family medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →